GeneQuantum Healthcare of Suzhou raised $5.8 million to advance its development of novel antibody drug conjugates toward IND filings. Founded in 2013, GeneQuantum says its proprietary next-generation Ligase Dependent Conjugation (LDC) technology allows the company to conjugate anti-tumor cytotoxins and site-specific antibodies with a much larger therapeutic window. GeneQuantum’s A round funding was led by Oriza Seed Venture Capital and joined by TF Capital.
